NasdaqCM:VICL

Stock Analysis Report

Executive Summary

Vical Incorporated researches and develops biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.

Snowflake

Fundamentals

Flawless balance sheet and overvalued.

Share Price & News

How has Vical's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-21.0%

VICL

3.1%

US Biotechs

1.8%

US Market


1 Year Return

-93.4%

VICL

-7.9%

US Biotechs

7.3%

US Market


Shareholder returns

VICLIndustryMarket
7 Day-21.0%3.1%1.8%
30 Day-87.0%-2.4%-0.7%
90 Day-88.2%-0.8%0.06%
1 Year-93.4%-93.4%-7.1%-7.9%9.7%7.3%
3 Year-97.5%-97.5%14.2%10.3%46.3%36.9%
5 Year-99.2%-99.2%0.07%-4.8%64.5%46.5%

Price Volatility Vs. Market

How volatile is Vical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Vical undervalued compared to its fair value and its price relative to the market?

0.053x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate VICL's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate VICL's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: VICL is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: VICL is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate VICL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: VICL is good value based on its PB Ratio (0.1x) compared to the US Biotechs industry average (2.6x).


Next Steps

Future Growth

How is Vical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

23.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if VICL's forecast earnings growth is above the savings rate (2.7%).

Earnings vs Market: Insufficient data to determine if VICL's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if VICL's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if VICL's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Information is not available.


Next Steps

Past Performance

How has Vical performed over the past 5 years?

-0.07%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: VICL is unprofitable, and losses have increased over the past 5 years at a rate of -0.07% per year.

Accelerating Growth: Unable to compare VICL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VICL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (78.4%).


Return on Equity

High ROE: VICL has a negative Return on Equity (-29.18%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: VICL is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: VICL is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Vical's financial position?


Financial Position Analysis

Short Term Liabilities: VICL's short term assets ($42.7M) exceeds its short term liabilities ($1.2M)

Long Term Liabilities: VICL has no long term liabilities


Debt to Equity History and Analysis

Debt Level: VICL is debt free.

Reducing Debt: VICL has not had any debt for past 5 years.


Balance Sheet

Information is not available.

Information is not available.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VICL has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: VICL has sufficient cash runway for 2.434560 years if free cash flow continues to reduce at historical rates of -28.8% each year.


Next Steps

Dividend

What is Vical's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.7%industryaverage2.0%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate VICL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate VICL's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if VICL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VICL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of VICL's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Vical's salary, the management and board of directors tenure and is there insider trading?

2.3yrs

Average management tenure


CEO

Vijay Samant (66yo)

18.8yrs

Tenure

US$1,029,354

Compensation

Mr. Vijay B. Samant has been the Chief Executive Officer and President of Vical Incorporation since November 2000. Mr. Samant joined Vical Inc. in November 2000. He served as Acting Chief Financial Officer ...


CEO Compensation Analysis

Information is not available.

Compensation vs Earnings: Vijay's compensation has been consistent with company performance over the past year.


Management Age and Tenure

2.3yrs

Average Tenure

58yo

Average Age

Experienced Management: VICL's management team is considered experienced (2.3 years average tenure).


Board Age and Tenure

12.2yrs

Average Tenure

68yo

Average Age

Experienced Board: VICL's board of directors are seasoned and experienced ( 12.2 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SellUS$1,930,70614 Jan 19
Armistice Capital LLC
EntityCompany
Shares312,928.48
Max PriceUS$6.17

Ownership Breakdown


Management Team

  • Vijay Samant (66yo)

    CEO, President & Director

    • Tenure: 18.8yrs
    • Compensation: US$1.03m
  • Tony Ramos (52yo)

    VP & CFO

    • Tenure: 2.3yrs
    • Compensation: US$433.47k
  • Larry Smith (58yo)

    Consultant

    • Tenure: 0.3yrs
    • Compensation: US$441.62k

Board Members

  • Gary Lyons (68yo)

    Director

    • Tenure: 22.5yrs
    • Compensation: US$65.70k
  • Richard Beleson (65yo)

    Director

    • Tenure: 6.3yrs
    • Compensation: US$55.70k
  • Vijay Samant (66yo)

    CEO, President & Director

    • Tenure: 18.8yrs
    • Compensation: US$1.03m
  • Greg Morrow (67yo)

    Director

    • Tenure: 6.9yrs
    • Compensation: US$70.70k
  • R. Douglas (84yo)

    Chairman of the Board

    • Tenure: 0yrs
    • Compensation: US$83.79k
  • Tom Shenk (72yo)

    Director

    • Tenure: 3.8yrs
    • Compensation: US$55.70k
  • Robert Merton (74yo)

    Director

    • Tenure: 17.5yrs
    • Compensation: US$73.70k

Company Information

Vical Incorporated's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Vical Incorporated
  • Ticker: VICL
  • Exchange: NasdaqCM
  • Founded: 1987
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$15.441m
  • Shares outstanding: 3.26m
  • Website: https://www.vical.com

Number of Employees


Location

  • Vical Incorporated
  • 10390 Pacific Center Court
  • San Diego
  • California
  • 92121
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
VICLNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDMar 1993
VCC1DB (Deutsche Boerse AG)YesCommon StockDEEURMar 1993

Biography

Vical Incorporated researches and develops biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company was founde ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/03 23:49
End of Day Share Price2019/08/30 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.